Advanced Search

Extraction Form Preview:

Corticosteroid implants for chronic non-infectious uveitis 2016


Arm Name Suggestions

Arm Title Arm Description User Note
Fluocinolone acetonide
Dexamethasone intravitreous

Arm Details

Question 1
...
...
...
Question 2
...
...
...
Question 3
...
...
...
Question 4

Design Details and Enrollment

Question 1
Question 2
Question 3
Question 4
Question 5
Question 6
Question 7
Question 8
Question 9
Question 10
Question 11
Question 12
Question 13
Question 14
Question 15
Question 16
Question 17
Question 18
Question 19
Question 20
Question 21
Question 22
Question 23
Question 24
Question 25
Question 26
Question 27
Question 28
Question 29
Question 30
Question 31
Question 32
Question 33
Question 34
Question 35
Question 36
Question 37
Question 38
Question 39
Question 40
Question 41
Question 42
Question 43
Question 44
Question 45
Question 46
Question 47
Question 48
Question 49
Question 50
Question 51
Question 52
Question 53
Question 54
Question 55
Question 56
Question 57
Question 58
Question 59
Question 60
Question 61
Question 62
Question 63
Question 64
Question 65
Question 66
Question 67
Question 68
Question 69
Question 70

Outcome Name Suggestions

Outcome Title Note
Proportion of participants with a recurrence of uveitis Proportion of participants with a recurrence of uveitis at 6 months. We defined recurrence as any of the following: increase in vitreous haze by two or more steps above baseline; increase in anterior chamber cell by two or more steps above baseline; need
Mean difference in BCVA Mean difference in best-corrected distance visual acuity (BCVA) as measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, Snellen chart, or Snellen equivalent.
Mean difference in quality of life Mean difference in quality of life (mean difference in any validated measures presented, e.g. National Eye Institute Visual Functioning Questionnaire (NEI-VFQ), 36-Item Short Form Health Survey (SF-36)).


Outcome Details

Question 1




Question 2
Row Headers
Yes
No
Baseline
One or more time points after baseline and ≤6 months
One or more time points after baseline >6 months and ≤12 months
One or more time points after baseline >12 months and ≤24 months
Question 3

Adverse Events

Arm or Total Title Description Proportion of adverse events
Fluocinolone acetonide
Dexamethasone intravitreous